结合疫苗市场－全球产业规模、份额、趋势、机会、预测：按产品类型、疾病适应症、最终用户、地区和竞争格局划分，2021-2031年

全球结合疫苗市场预计将从 2025 年的 196.9 亿美元成长到 2031 年的 340.5 亿美元，复合年增长率为 9.56%。

这些疫苗是透过将弱抗原（通常是细菌多醣）共用价结合到载体蛋白上而製成的，这一过程能够引发强烈的免疫反应。这种化学结合将T细胞非依赖性抗原转化为T细胞依赖性抗原，从而有效诱导免疫记忆并确保疫苗对婴幼儿的有效性。该领域的发展主要得益于肺炎球菌和脑膜炎球菌病菌感染在全球范围内的日益蔓延、这些生物製药被频繁纳入国家免疫规划，以及国际组织对开发中国家疫苗接种活动的大量资金支持。

儘管存在这些市场驱动因素，但市场仍面临许多障碍，例如高昂的製造成本和复杂的生产工艺，导致资源匮乏地区难以获得这些产品。这些复杂的生产要求造成供应瓶颈和价格上涨，阻碍了全民普及。例如，世界卫生组织（世卫组织）在2025年报告称，到2024年底，肺炎球菌结合疫苗将在163个成员国投入使用，实现全球67%的三剂接种覆盖率。这项数据既凸显了这些生物製药的广泛可及性，也反映了全球免疫覆盖率仍然存在的差距。

市场驱动因素

世界卫生组织加强疫苗供应的策略性倡议正在从根本上改变市场格局。这些组织正与各国政府合作，将结合疫苗纳入国家规划，尤其是在非洲脑膜炎带等高负担地区。透过保障供应链和补贴采购成本，这些措施确保了拯救生命的疫苗能够惠及先前缺乏足够服务的弱势族群。一个显着的例子是，一种新型五价脑膜炎双球菌结合疫苗被纳入一个非洲主要国家的公共卫生策略。根据全球疫苗免疫联盟（Gavi）2024年4月发布的关于尼日利亚Men5CV疫苗上市的新闻稿，该联盟透过支持一项旨在控制疫情、覆盖一百万人的紧急宣传活动，展现了这些协调努力的规模。

同时，强大的临床开发平臺和新型多价疫苗的上市正在推动市场成长并扩大保护范围。製造商正将重点从儿童特定适应症转向全面的成人策略，开发覆盖更广泛血清型的製剂以降低抗生素抗药性。这项创新旨在提供对不断演变的细菌菌株的更广泛保护，并为医护人员提供更强大的侵袭性疾病预防工具。作为这项进展的象征，默克公司于2024年6月宣布，首款专为成人设计的21价肺炎链球菌结合疫苗CAPVAXIVE已获得FDA核准。这些商业性里程碑直接转化为巨大的经济价值。例如，辉瑞公司报告称，光是2024年第三季度，其Prevner产品系列的全球销售额就达到了18亿美元。

市场挑战

阻碍全球结合疫苗市场成长的主要障碍是其生产流程相关的高昂成本和技术复杂性。这些生物製药的生产需要复杂的化学偶联工艺，将细菌多醣与蛋白质载体连接起来，这需要高度专业的设施和先进的技术。这些严格的生产标准要求对基础设施和品管系统进行大量资本投资，从而为新生产商设置了很高的进入门槛。因此，市场仍然集中在大型製药企业手中，限制了竞争，并推高了价格，从而限制了对成本敏感的市场中的采购。

这种生产能力的集中导致供应链脆弱性和获取不均，尤其是在当地生产能力欠发达的发展中地区。由于无法在本地生产复杂的配方，不得不依赖昂贵的进口产品，这往往导致供不应求和市场渗透延迟。例如，全球疫苗免疫联盟（Gavi）在2024年发布的报告显示，非洲大陆的疫苗产量仅占全球供应量的约0.1%，这意味着该地区几乎完全依赖进口疫苗。缺乏分散的生产能力阻碍了高效拓展市场至高需求且资源有限的地区的潜力。

市场趋势

合成结合疫苗生产技术的进步正在从根本上改变疫苗生产模式，超越了传统的化学偶联方法。这一趋势的特点是采用无细胞蛋白合成和特异性偶联技术，克服了传统生产过程的技术限制。与添加多种血清型时面临载体抑制和空间位阻等问题的标准製程不同，合成平台能够在不影响免疫抗原性的前提下，精确组装高价值的多血清型製剂。大量资金涌入采用这些技术的公司，充分证明了这项技术转变的商业性可行性。例如，2024年9月，Vaxcyte宣布透过首次股票公开发行资金筹措亿美元，用于推进其旨在提供更广泛保护的合成疫苗研发管线。

同时，非传染性疾病治疗性结合疫苗的出现表明，市场关注正从传统感染疾病转向其他领域。研究人员和新兴企业正在加速将结合技术应用于物质使用疾患的治疗，他们开发出的製剂中，Fentanyl和海洛因衍生物等药物半抗原与免疫抗原性载体蛋白结合。这些疫苗透过诱导产生抗体来中和药物的精神活性作用，这些抗体能够捕获血液中的目标药物，从而阻止药物穿过血脑障壁。这项应用正在将目标市场拓展到成瘾治疗领域，并吸引新的投资。根据《达拉斯晨报》2024年9月报道，生物製药Start-UpsObax截至2024年6月已筹集超过1000万美元，用于推进一种新型Fentanyl结合疫苗的人体资金筹措试验。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球结合疫苗市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品类型（单价合併疫苗、多价合併疫苗）
  • 特定疾病（肺炎链球菌、流感、脑膜炎双球菌、伤寒）
  • 依最终使用者（医院/诊所、门诊中心、其他）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美结合疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲结合疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区结合疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲结合疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲结合疫苗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球结合疫苗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Sanofi SA
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Conjugate Vaccine Market is projected to expand from USD 19.69 Billion in 2025 to USD 34.05 Billion by 2031, reflecting a compound annual growth rate of 9.56%. These vaccines are created by covalently bonding a weak antigen, typically a bacterial polysaccharide, to a carrier protein, a process that triggers a robust immune response. This chemical linkage transforms T-cell independent antigens into T-cell dependent ones, effectively inducing immunological memory and ensuring potency in infants. Growth in this sector is largely fueled by the increasing global prevalence of pneumococcal and meningococcal diseases, alongside the frequent inclusion of these biologics in national immunization protocols and substantial financial support from international bodies for vaccination efforts in developing countries.

Despite these drivers, the market encounters significant obstacles due to the high costs and intricate nature of manufacturing, which limits availability in resource-constrained regions. These complex production demands frequently result in supply bottlenecks and elevated prices that hinder universal access. To illustrate the current scale of deployment, the World Health Organization reported in 2025 that the pneumococcal conjugate vaccine had been introduced in 163 Member States by late 2024, achieving a global third-dose coverage of 67%. This statistic underscores both the widespread distribution of these biologics and the persistent gaps remaining in global immunization coverage.

Market Driver

Strategic initiatives by global health organizations to enhance vaccine availability are fundamentally reshaping the market landscape. These entities collaborate with governments to introduce conjugate vaccines into national programs, particularly in high-burden areas such as the African meningitis belt. By securing supply chains and subsidizing procurement costs, these initiatives ensure that life-saving formulations reach vulnerable populations that were previously underserved. A prime example of this expansion occurred when a major African nation integrated a novel pentavalent meningococcal conjugate vaccine into its public health strategy. According to Gavi, the Vaccine Alliance, in an April 2024 press release regarding Nigeria's introduction of the Men5CV vaccine, the alliance supported an emergency campaign targeting 1 million people to halt an outbreak, demonstrating the scale of these coordinated efforts.

Concurrently, a strong clinical pipeline and the launch of novel multivalent vaccines are driving market growth and broadening the scope of protection. Manufacturers are increasingly shifting focus from pediatric-only indications to comprehensive adult strategies, developing formulations that cover a wider array of serotypes to mitigate antimicrobial resistance. This innovation aims to provide broader coverage against evolving bacterial strains, offering healthcare providers more potent tools to prevent invasive disease. Highlighting this advancement, Merck & Co., Inc. announced in June 2024 that the FDA approved CAPVAXIVE, the first 21-valent pneumococcal conjugate vaccine specifically designed for adults. Such commercial milestones translate into significant financial value; for instance, Pfizer Inc. reported that its Prevnar franchise generated $1.8 billion in global revenues during the third quarter of 2024 alone.

Market Challenge

The primary obstacle hampering the growth of the Global Conjugate Vaccine Market is the substantial cost and technical complexity associated with the manufacturing process. Producing these biologics requires intricate chemical conjugation procedures to link bacterial polysaccharides with protein carriers, a step that demands highly specialized facilities and advanced technical expertise. These rigorous production standards necessitate significant capital investment in infrastructure and quality control systems, creating high barriers to entry for new manufacturers. Consequently, the market remains concentrated among a limited number of major pharmaceutical players, which restricts competition and keeps unit prices elevated, thereby limiting procurement volumes in cost-sensitive markets.

This concentration of manufacturing capacity results in supply chain vulnerabilities and unequal access, particularly in developing regions where local production capabilities are absent. The inability to manufacture these complex formulations locally forces reliance on expensive imports, which often leads to supply shortages and slower market penetration. Illustrating this disparity, Gavi, the Vaccine Alliance reported in 2024 that the African continent produced only approximately 0.1% of the global vaccine supply, leaving the region almost entirely dependent on imported doses. This lack of distributed manufacturing capability hampers the market's potential to expand efficiently into high-demand, resource-constrained geographies.

Market Trends

Advancements in synthetic conjugate vaccine manufacturing are fundamentally altering production paradigms by moving beyond traditional chemical conjugation methods. This trend is characterized by the adoption of cell-free protein synthesis and site-specific linkage technologies, which circumvent the technical limitations of conventional manufacturing. Unlike standard processes that struggle with carrier suppression and steric hindrance when adding multiple serotypes, synthetic platforms enable the precise assembly of high-valency formulations without compromising immunogenicity. The commercial viability of this technological shift is evident in the substantial capital flowing into companies pioneering these methods; for example, Vaxcyte, Inc. announced in September 2024 that it raised significant funds through a $1.3 billion public offering to advance its synthetic vaccine pipeline aimed at producing broader-spectrum protection.

Simultaneously, the emergence of therapeutic conjugate vaccines for non-communicable diseases represents a divergence from the market's traditional infectious disease focus. Researchers and startups are increasingly leveraging conjugate technology to treat substance use disorders by engineering formulations where drug haptens, such as fentanyl or heroin derivatives, are coupled to immunogenic carrier proteins. These vaccines induce the production of antibodies that sequester the target drug in the bloodstream, preventing it from crossing the blood-brain barrier and thereby neutralizing its psychoactive effects. This application expands the addressable market into addiction medicine, attracting new streams of investment. As reported by The Dallas Morning News in September 2024, the biopharmaceutical startup Ovax had raised over $10 million by June 2024 to progress a novel fentanyl conjugate vaccine into human clinical trials.

Key Market Players

• Sanofi S.A
• Pfizer Inc.
• Merck & Co. Inc.
• GlaxoSmithKline plc
• Bharat Biotech International Limited
• Serum Institute of India Pvt. Ltd
• Biological E. Limited
• Bavarian Nordic A/S
• CSL Limited
• Novartis AG

Report Scope

In this report, the Global Conjugate Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Conjugate Vaccine Market, By Product Type

• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccine

Conjugate Vaccine Market, By Disease Indication

• Pneumococcal
• Influenza
• Meningococcal
• Typhoid

Conjugate Vaccine Market, By End-User

• Hospitals & Clinics
• Ambulatory care Centers
• Others

Conjugate Vaccine Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Conjugate Vaccine Market.

Available Customizations:

Global Conjugate Vaccine Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Conjugate Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine)
  • 5.2.2. By Disease Indication (Pneumococcal, Influenza, Meningococcal, Typhoid)
  • 5.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Conjugate Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By Disease Indication
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Conjugate Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By Disease Indication
      • 6.3.1.2.3. By End-User
  • 6.3.2. Canada Conjugate Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By Disease Indication
      • 6.3.2.2.3. By End-User
  • 6.3.3. Mexico Conjugate Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By Disease Indication
      • 6.3.3.2.3. By End-User

7. Europe Conjugate Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By Disease Indication
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Conjugate Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By Disease Indication
      • 7.3.1.2.3. By End-User
  • 7.3.2. France Conjugate Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By Disease Indication
      • 7.3.2.2.3. By End-User
  • 7.3.3. United Kingdom Conjugate Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By Disease Indication
      • 7.3.3.2.3. By End-User
  • 7.3.4. Italy Conjugate Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By Disease Indication
      • 7.3.4.2.3. By End-User
  • 7.3.5. Spain Conjugate Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By Disease Indication
      • 7.3.5.2.3. By End-User

8. Asia Pacific Conjugate Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By Disease Indication
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Conjugate Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By Disease Indication
      • 8.3.1.2.3. By End-User
  • 8.3.2. India Conjugate Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By Disease Indication
      • 8.3.2.2.3. By End-User
  • 8.3.3. Japan Conjugate Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By Disease Indication
      • 8.3.3.2.3. By End-User
  • 8.3.4. South Korea Conjugate Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product Type
      • 8.3.4.2.2. By Disease Indication
      • 8.3.4.2.3. By End-User
  • 8.3.5. Australia Conjugate Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product Type
      • 8.3.5.2.2. By Disease Indication
      • 8.3.5.2.3. By End-User

9. Middle East & Africa Conjugate Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By Disease Indication
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Conjugate Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By Disease Indication
      • 9.3.1.2.3. By End-User
  • 9.3.2. UAE Conjugate Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By Disease Indication
      • 9.3.2.2.3. By End-User
  • 9.3.3. South Africa Conjugate Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By Disease Indication
      • 9.3.3.2.3. By End-User

10. South America Conjugate Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By Disease Indication
  • 10.2.3. By End-User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Conjugate Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By Disease Indication
      • 10.3.1.2.3. By End-User
  • 10.3.2. Colombia Conjugate Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By Disease Indication
      • 10.3.2.2.3. By End-User
  • 10.3.3. Argentina Conjugate Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By Disease Indication
      • 10.3.3.2.3. By End-User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Conjugate Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sanofi S.A
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc.
• 15.3. Merck & Co. Inc.
• 15.4. GlaxoSmithKline plc
• 15.5. Bharat Biotech International Limited
• 15.6. Serum Institute of India Pvt. Ltd
• 15.7. Biological E. Limited
• 15.8. Bavarian Nordic A/S
• 15.9. CSL Limited
• 15.10. Novartis AG

16. Strategic Recommendations

17. About Us & Disclaimer